Table 1: Clinical and pathological features for 55 cases of DGIST associate with disease-free survival (DFS) and overall-survival (OS).

CharacteristicN (%)DFS (month)Chi-square value valueOS (month)Chi-square value value

Gender3.3830.0663.4510.063
 Male26 (47.27)101.7 ± 10.91122.5 ± 11.10
 Female29 (52.73)137.4 ± 9.292147.3 ± 7.249
Age0.5840.4450.0470.829
 ≥6015 (27.27)132.2 ± 12.26130.3 ± 12.91
 <6040 (72.73)120.8 ± 9.744138.3 ± 7.716
Symptoms0.010.9210.350.554
 Asymptomatic6 (10.91)
 Abdominal pain/distention17 (30.91)
 Hemorrhage/anemia31 (56.36)
 Abdominal mass1 (1.82)
Surgical method2.160.1421.3080.253
 Whipple/child18 (32.73)63.30 ± 6.77173.58 ± 4.941
 Local resection37 (67.27)131.6 ± 8.522140.0 ± 6.8
Growth pattern2.6370.2680.620.733
 Exophytic growth37 (67.3)121.7 ± 7.185123.2 ± 8.342
 Intraluminal growth10 (18.2)94.14 ± 19.40144.0 ± 8.981
 Both8 (14.5)116.8 ± 21.05117.8 ± 20.39
Tumor size4.2810.0394.8670.027
 ≤5 cm17 (30.91)135.1 ± 8.105144.4 ± 6.695
 >5 cm38 (69.09)101.9 ± 15.67112.7 ± 16.32
Tumor size0.0030.9580.0390.844
 ≤2 cm9 (16.36)121.8 ± 14.76132.7 ± 4.355
 2~5 cm29 (52.73)135.4 ± 8.946146.1 ± 8.200
Site2.5480.4672.4960.476
 Bulb6 (10.91)
 Descending27 (49.09)
 Horizontal21 (38.18)
 Ascending1 (1.818)
Mitotic activity14.250.00110.050.007
 <5/50 HPF40 (72.73)123.3 ± 9.080144.4 ± 6.695
 5~10/50 HPF9 (16.36)103.4 ± 17.88121.5 ± 18.29
 >10/50 HPF6 (10.91)40.29 ± 6.04759.60 ± 10.65
Ki-67 index26.21<0.00112.92<0.001
 ≤5%38 (69.09)147.3 ± 5.136151.5 ± 3.492
 >5%17 (30.91)43.88 ± 6.00092.53 ± 12.63
Pathological risk25.280.005110.012
 Very low9 (16.36)
 Low24 (43.64)
 Intermediate9 (16.36)
 High13 (23.64)
Imatinib after surgery for middle-high pathological risk0.4780.4890.0620.804
 Yes6 (27.27)41.17 ± 7.53158.00 ± 11.43
 No16 (72.73)111.3 ± 14.79122.7 ± 14.55
Imatinib after recurrence9.8110.002
 Yes6 (54.55)125.6 ± 12.16
 No5 (45.45)35.73 ± 12.71